Role of angiotensin in pressure overload-induced hypertrophy in rats: Effects of angiotensin-converting enzyme inhibitors, an AT1 receptor antagonist, and surgical reversal

Journal of Cardiovascular Pharmacology

Volumn 2, Issue 2, 1994, Pages 291-299

  Mohabir, Rajendra ^a   Young, Susan D ^a  

^a ROCHE BIOSCIENCE   (United States)

Author keywords

Angiotensin converting enzyme inhibitors; Aortic banding; Enalapril; Hypertrophy; Losartan; Ramipril

Indexed keywords

ANGIOTENSIN; ANGIOTENSIN RECEPTOR; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; LOSARTAN; RAMIPRIL;

ANIMAL MODEL; ANIMAL TISSUE; ANTIHYPERTENSIVE THERAPY; AORTA STENOSIS; ARTICLE; CONTROLLED STUDY; ENZYME INHIBITION; HEART LEFT VENTRICLE HYPERTROPHY; HYPERTENSION; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RAT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

ANGIOTENSIN I; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMAL; AORTA, ABDOMINAL; BIPHENYL COMPOUNDS; BLOOD PRESSURE; BODY WEIGHT; CARDIOMEGALY; COMPARATIVE STUDY; ENALAPRIL; HEART VENTRICLE; IMIDAZOLES; LOSARTAN; MALE; ORGAN WEIGHT; RAMIPRIL; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, ANGIOTENSIN; RENIN-ANGIOTENSIN SYSTEM; TETRAZOLES;

EID: 0027976362     PISSN: 01602446     EISSN: 15334023     Source Type: Journal    
DOI: 10.1097/00005344-199411000-00017     Document Type: Article

References (37)

1. Kannel WB, Belanger AJ. Epidemiology of heart failure. Am Heart J 1991;121:951-7.
2. Leenen FHH, Harmsen E. Antihypertensive drugs and cardiac trophic mechanisms. J Cardiovasc Pharmacol 1991; 17(suppl 2):S50-7.
3. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure: Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987;316:1429-35.
4. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991;325:293-302.
5. Cohn JN, Johnson G, Ziesche S, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic heart failure. N Engl J Med 1991;325:303-10.
6. Kromer EP, Riegger GAJ. Effects of long-term angiotensin converting enzyme inhibition on myocardial hypertrophy in experimental aortic stenosis in the rat. Am J Cardiol 1988;62:161-3.
7. Linz W, Scholkens BA, Ganten D. Converting enzyme inhibition specifically prevents the development and induces regression of cardiac hypertrophy in rats. Clin Exp Hyper-tens [A] 1989;11:1325-50.
8. Baker KM, Chemin MI, Wixson SK, Aceto JF. Renin-angiotensin system involvement in pressure-overload cardiac hypertrophy in rats. Am J Physiol 1990;259:H324-32.
9. Lindpainter K, Ganten D. The cardiac renin-angiotensin system. An appraisal of present experimental and clinical evidence. Cire Res 1991;68:905-21.
10. Timmermans PBMWM, Wong PC, Chiu AT, Herblin WF. Nonpeptide angiotensin II receptor antagonists. Trends Pharmacol Sei 1991;12:55-62.
11. Field KJ, Lang CM. Hazards of urethane (ethyl carbamate): A review of the literature. Lab Anim 1988;22:255-62.
12. Cohen ML, Kurz KD. Angiotensin converting enzyme inhibition in tissues from spontaneously hypertensive rats after treatment with captopril or MK-421. J Pharmacol Exp Ther 1982;220:63-9.
13. Unger T, Ganten D, Lang RE, Scholkens BA. Persistent tissue converting enzyme inhibition following chronic treatment with HOE 498 and MK 421 in spontaneously hypertensive rats. J Cardiovasc Pharmacol 1985;7:36-41.
14. Katz AM. Angiotensin II: Hemodynamic regulator or growth factor? J Mol Cell Cardiol 1990;22:739-47.
15. Wong PC, Price WA, Chiu AT, et al. Nonpeptide angiotensin II receptor antagonists. IX. Antihypertensive activity in rats of DuP 753, an orally active antihypertensive agent. J Pharmacol Exp Ther 1990;252:726-32.
16. Linz W, Henning R, Scholkens BA. Role of angiotensin Il receptor antagonism and converting enzyme inhibition in the progression and regression of cardiac hypertrophy in rats. J Hypertens 1991;9(suppl 6):S400-1.
17. Carretero OA, Scicli AG. Zinc metallopeptidase inhibitors. A novel antihypertensive treatment. Hypertension 1991;68:366-71.
18. Linz W, Scholkens BA. A specific B2-bradykinin receptor antagonist HOE 140 abolishes the antihypertrophic effect of ramipril. Br J Pharmacol 1992;105:771-2.
19. Schelling P, Fischer H, Ganten D. Angiotensin and cell growth: A link to cardiovascular hypertrophy? J Hypertens 1991;9:3-15.
20. Baker KM, Aceto JF. Angiotensin II stimulation of protein synthesis and cell growth in chick heart cells. Am J Physiol 1990;259:H610-8.
21. Urata H, Healy B, Stewart RW, Bumpus FM, Husain A. Angiotensin receptors in normal and failing human hearts. J Clin Endocrinol Metab 1989;69:54-66.
22. Mizuno K, Tani M, Hashimoto S, Niimura S, et al. Effects of losartan, a nonpeptide angiotensin Il receptor antagonist, on cardiac hypertrophy and the tissue angiotensin content in spontaneously hypertensive rats. Life Sci 1992;51:367-74.
23. Bishop SP, Chen CW, Doss L, Streenan C. Lack of effect of captopril on myocardial hypertrophy and myocyte remodeling in abdominal aortic constricted rats. J Mol Cell Cardiol 1992;24(suppl III):S36.
24. Zierhut W, Zimmer HG, Gerdes AM. Effect of angiotensin converting enzyme inhibition on pressure-induced left ventricular hypertrophy. Circ Res 1991;69:609-17.
25. Dostal DE, Baker KM. Angiotensin II stimulation of left ventricular hypertrophy in adult rat heart. Mediation by the AT, receptor. Am J Hypertens 1992;5:276-80.
26. Pfeffer JM, Pfeffer MA, Mirsky I, Braunwald E. Regression of left ventricular hypertrophy and prevention of left ventricular dysfunction by captopril in the spontaneously hypertensive rat. Proc Natl Acad Sci USA 1982;79:3310-4.
27. Nagano M, Higaki J, Mikami H, et al. Converting enzyme inhibitors regressed cardiac hypertrophy and reduced tissue angiotensin II in spontaneously hypertensive rats. J Hyper-tens 1991;9:595-9.
28. Fröhlich ED, Horinaka S. Cardiac and aortic effects of angiotensin enzyme inhibitors. Hypertension 1991;18(suppl II):II-2-7.
29. Levy BI, Michel JB, Salzmann JL, Devissaguet M, Safar ME. Remodeling of heart and arteries by chronic converting enzyme inhibition in spontaneously hypertensive rats. J Hypertens 1991;4:240S-5S.
30. Linz W, Schapper J, Wiemer G, Albus U, Scholkens BA. Ramipril prevents left ventricular hypertrophy with myocardial fibrosis without blood pressure reduction: A one year study in rats. Br J Pharmacol 1992;107:970-5.
31. Bagby SP, McDonald WJ, Mass RD. Serial renin-angiotensin studies in spontaneously hypertensive and Wistar-Kyoto normotensive rats. Hypertension 1979;1:347-54.
32. Stasch JP, Kazda S, Hirth C. Effect of hypertension, cardiac hypertrophy and atrial natriuretic peptides of treatment with nifedipine in SHR. J Hypertens 1986;4(suppl 6):S160-2.
33. Morgan HE, Baker KM. Cardiac hypertrophy. Mechanical, neural, and endocrine dependence. Circulation 1991;83:13-25.
34. Schneider MD, Parker TG. Cardiac myocytes as targets for the action of peptide growth factors. Circulation 1990;81:1443-6.
35. Fuller SJ, Mynett JR, Sugden PH. Stimulation of cardiac protein synthesis by insulin-like growth factors. Biochem J 1992;282:85-90.
36. Suzuki T, Hoshi H, Mitsui Y. Endothelin stimulates hypertrophy and contractility of neonatal rat cardiac myocytes in a serum-free medium. FEBS Lett 1990;268:149-51.
37. Suzuki T, Hoshi H, Sasaki H, Mitsui Y. Endothelin-1 stimulates hypertrophy and contractility of neonatal rat cardiac myocytes in a serum-free medium. II. J Cardiovasc Pharmacol 1991;17(suppl 7):S182-6.